Chinese Pharmaceutical Firm Hisoar Added to U.S. Import Ban
- Hisoar operates 41st drug plant in China placed on FDA list
- FDA inspection of Hisoar plant found data integrity issues
This article is for subscribers only.
Zhejiang Hisoar Pharmaceutical Co., a Chinese company that makes ingredients for some of the world’s biggest brand-name drugmakers, has been banned from sending its products to the U.S.
The U.S. Food and Drug Administration inspected Hisoar in August and found that quality records had been deleted and test records had been altered, with failing results sometimes going unreported, Bloomberg reported last year. All of Hisoar’s drugs and ingredients, manufactured in the city of Taizhou, are subject to the import ban posted Wednesday.